RNS Number : 2185U
  Hikma Pharmaceuticals Plc
  12 May 2008
   

    Annual Information Update

    LONDON, 12 May 2008. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK and DFX:HIK)
sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The
information referred to in this Update was up to date at the time the information was published, but some information may now be out of
date.
    Stock Exchange announcements
    Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the London Stock Exchange
website (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at
(http://investors.hikma.com/hikma/regulatorynews.jsp). The Stock Exchange announcements made during the defined period are:
 Date of announcement  Headline of announcement
 30 Apr 08             LTIP Awards
 16 Apr 08             Director/PDMR Shareholding
 15 Apr 08             Notice of Annual Report
 11 Apr 08             Block listing - Six monthly review
 04 Apr 08             Voting Rights and Capital
 31 Mar 08             Director/PDMR Shareholding
 18 Mar 08             Preliminary Results
 04 Mar 08             Voting Rights and Capital
 07 Feb 08             Voting Rights and Capital 
 21 Jan 08             Notification of Transaction 
 17 Jan 08             Result of Equity Issue 
 17 Jan 08             Trading Update 
 17 Jan 08             Issue of Equity 
 08 Jan 08             Director/PDMR Shareholding 
 07 Jan 08             Director/PDMR Shareholding 
 02 Jan 08             Director/PDMR Shareholding 
 02 Jan 08             Director/PDMR Shareholding
 17 Dec 07             Director/PDMR Shareholding
 14 Dec 07             Pre-Close Trading Statement 
 10 Dec 07             Hikma Acquires APM
 30 Nov 07             Voting Rights and Capital 
 21 Nov 07             Update on Lisinopril Contract 
 31 Oct 07             Legal and General DTR Announcement 
 15 Oct 07             Director/PDMR Shareholding
 08 Oct 07             Conditional Cash Offer 
 08 Oct 07             Block Listing of Shares 
 05 Oct 07             Block Listing - 6month Review 
 19 Sep 07             Option Exercise 
 14 Sep 07             Director/PDMR Shareholding
 11 Sep 07             Notification of Transaction
 07 Sep 07             Notification of Transaction
 05 Sep 07             Interim Results 2007 
 09 Aug 07             Hikma Enters Egyptian Market 
 27 Jun 07             Pre-Close Trading Statement 
 06 Jun 07             AGM Statement 

    Any related documents are available at the UKLA's Document Viewing Facility, Financial Services Authority, 25 the North Colonnade,
London, E14 5HS. 
    All of the above announcements were also made by the Company via the Dubai International Financial Exchange ("DIFX") CANDI system. These
announcements may be viewed and downloaded from the DIFX website (www.difx.ae).  
    Documents filed with Companies House
    The Company submitted filings to Companies House, in relation to the Company's annual return, financial report & accounts, appointments
and resignations of directors, allotments of shares and ordinary and special resolutions passed at the Company's 2007 Annual General
Meeting. Copies of all these documents can be found on the Companies House website at www.companieshouse.gov.uk or through Companies House
Direct at www.direct.companieshouse.gov.uk.
    Henry Knowles
Company Secretary
12 May 2008
    - ENDS -

    Enquiries:


 Hikma Pharmaceuticals plc
 Henry Knowles, Company Secretary     +44 20 7399 2760
 Susan Ringdal, Investor Relations
 Director
 Brunswick Group LLP    
 Jon Coles / Justine    
 McIlroy / Alex Tweed   

  

    +44 20 7404 5959


    Notes to Editors

    About Hikma
    Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both
branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics".  Hikma's operations are based principally in the Middle East and North Africa ("MENA") region,
where it is a market leader and sells across 17 countries, the United States and Europe.  In 2007, the Group achieved revenues of $449
million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million).  For news and other information,
please visit www.hikma.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
AIUZLLFFVEBLBBE
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.